Bristol-Myers Squibb (NYSE:BMY) Stock Holdings Boosted by Larson Financial Group LLC

Larson Financial Group LLC lifted its position in Bristol-Myers Squibb (NYSE:BMY) by 10.6% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 17,100 shares of the biopharmaceutical company’s stock after buying an additional 1,639 shares during the period. Larson Financial Group LLC’s holdings in Bristol-Myers Squibb were worth $967,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. HM Payson & Co. raised its position in Bristol-Myers Squibb by 8.4% in the fourth quarter. HM Payson & Co. now owns 97,869 shares of the biopharmaceutical company’s stock worth $5,535,000 after acquiring an additional 7,583 shares in the last quarter. Generali Investments CEE investicni spolecnost a.s. acquired a new position in shares of Bristol-Myers Squibb in the 4th quarter worth approximately $1,012,000. Bank Julius Baer & Co. Ltd Zurich raised its holdings in shares of Bristol-Myers Squibb by 5.7% in the 4th quarter. Bank Julius Baer & Co. Ltd Zurich now owns 2,336,579 shares of the biopharmaceutical company’s stock worth $140,533,000 after purchasing an additional 125,830 shares in the last quarter. Machina Capital S.A.S. lifted its stake in Bristol-Myers Squibb by 36.7% during the fourth quarter. Machina Capital S.A.S. now owns 36,572 shares of the biopharmaceutical company’s stock valued at $2,069,000 after purchasing an additional 9,820 shares during the last quarter. Finally, Aviance Capital Partners LLC boosted its holdings in Bristol-Myers Squibb by 4.7% during the fourth quarter. Aviance Capital Partners LLC now owns 36,018 shares of the biopharmaceutical company’s stock worth $2,037,000 after buying an additional 1,605 shares in the last quarter. Institutional investors and hedge funds own 76.41% of the company’s stock.

Bristol-Myers Squibb Price Performance

BMY opened at $61.16 on Monday. The company has a debt-to-equity ratio of 2.90, a current ratio of 1.25 and a quick ratio of 1.15. The stock has a market capitalization of $124.11 billion, a P/E ratio of -13.84, a price-to-earnings-growth ratio of 2.07 and a beta of 0.43. The company’s 50 day simple moving average is $57.39 and its 200-day simple moving average is $55.17. Bristol-Myers Squibb has a one year low of $39.35 and a one year high of $63.11.

Bristol-Myers Squibb (NYSE:BMY) last announced its quarterly earnings data on Thursday, February 6th. The biopharmaceutical company reported $1.67 EPS for the quarter, beating analysts’ consensus estimates of $1.47 by $0.20. Bristol-Myers Squibb had a positive return on equity of 13.93% and a negative net margin of 18.53%. Sell-side analysts anticipate that Bristol-Myers Squibb will post 6.74 earnings per share for the current fiscal year.

Bristol-Myers Squibb Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, May 1st. Shareholders of record on Friday, April 4th will be issued a dividend of $0.62 per share. The ex-dividend date of this dividend is Friday, April 4th. This represents a $2.48 annualized dividend and a yield of 4.05%. Bristol-Myers Squibb’s dividend payout ratio is currently -56.11%.

Insider Buying and Selling at Bristol-Myers Squibb

In other Bristol-Myers Squibb news, EVP Samit Hirawat purchased 1,823 shares of the company’s stock in a transaction that occurred on Friday, February 14th. The stock was acquired at an average cost of $54.84 per share, with a total value of $99,973.32. Following the completion of the purchase, the executive vice president now directly owns 63,932 shares in the company, valued at approximately $3,506,030.88. This represents a 2.94 % increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 0.09% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have issued reports on BMY shares. Wolfe Research assumed coverage on Bristol-Myers Squibb in a report on Friday, November 15th. They issued a “peer perform” rating on the stock. Truist Financial boosted their target price on Bristol-Myers Squibb from $62.00 to $65.00 and gave the stock a “buy” rating in a research report on Wednesday, January 8th. Bank of America reiterated a “neutral” rating and issued a $63.00 price target on shares of Bristol-Myers Squibb in a research report on Tuesday, December 10th. BMO Capital Markets boosted their price objective on Bristol-Myers Squibb from $57.00 to $61.00 and gave the stock a “market perform” rating in a report on Tuesday, November 12th. Finally, Daiwa America upgraded shares of Bristol-Myers Squibb from a “hold” rating to a “strong-buy” rating in a report on Wednesday, November 13th. Two analysts have rated the stock with a sell rating, twelve have assigned a hold rating, four have given a buy rating and three have given a strong buy rating to the company’s stock. According to MarketBeat.com, Bristol-Myers Squibb presently has a consensus rating of “Hold” and a consensus target price of $57.86.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.